RxDoctor Payments Data

Lauren Martin

Gerontology · Murfreesboro, TNNPI 1821553959

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.6% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 24.7% of the total. Reporting peaked in 2021 at $1,003 and has fallen 54.5% since, to $457 in 2025.

$2,092in general payments, 2019–2025

Across 108 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$517
  • Otsuka America Pharmaceutical, Inc.$302
  • Novo Nordisk$204
  • Fresenius USA Marketing, Inc.$196
  • Bayer$157
  • Akebia Therapeutics Inc$131
  • plus $585 from 13 others

What the payments were for

  • Food & beverage$1,93693%
  • Education$1567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,092 in reported general payments places this provider in the 85th percentile of 194 gerontology providers in Tennessee.

See all gerontology providers in Tennessee

Medicare billing

Part B allowed, 2024
$26,932
Medicare patients
232
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate15$43,349
VelphoroSucroferric Oxyhydroxide12$41,154
Sevelamer Carbonate36$4,223
Calcitriol48$449
Potassium Chloride23$391
Torsemide11$314
Furosemide46$138
Allopurinol28$101
Losartan Potassium17$86
Carvedilol20$66
Ciprofloxacin Hcl15$53
Tamsulosin Hcl21$43
Amlodipine Besylate12$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$131$43,34915 claims
Fresenius USA Marketing, Inc.Velphoro$196$41,15412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 194 gerontology providers in Tennessee.

Other gerontology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →